Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Aprea Therapeutics, Inc. (United States)
Homepage:
aprea.com
Alternate names:
Aprea AB,
Aprea Therapeutics,
Aprea Therapeutics AB,
Aprea Therapeutics, Inc.
ROR:
05ete2f36
OpenAlex ID:
I4405268024
Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
2021
·
David A. Sallman
, Amy E. DeZern
, et al.
·
Journal of Clinical Oncology
·
465
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes
2022
·
Asmita Mishra
, Roni Tamari
, et al.
·
Journal of Clinical Oncology
·
143
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study
2023
·
Guillermo Garcia-Manero
, Aaron D Goldberg
, et al.
·
The Lancet Haematology
·
88
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
2019
·
David A Sallman
, Amy E. DeZern
, et al.
·
Blood
·
73
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
2022
·
H. Park
, G.I. Shapiro
, et al.
·
ESMO Open
·
47
PDF
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
2021
·
David A. Sallman
, Rami S. Komrokji
, et al.
·
Blood
·
37
Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML)
2021
·
Guillermo Garcia-Manero
, Aaron D Goldberg
, et al.
·
Blood
·
22
Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT)
2021
·
Asmita Mishra
, Roni Tamari
, et al.
·
Blood
·
18
Abstract 6177: ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment
2023
·
Joseph Vacca
, Stephen Rocca
, et al.
·
Cancer Research
·
4
Abstract CT196: First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors
2024
·
Fiona Simpkins
, Amit Mahipal
, et al.
·
Cancer Research
·
3
Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.
2021
·
Ecaterina Elena Dumbrava
, Amit Mahipal
, et al.
·
Journal of Clinical Oncology
·
3
Abstract CT195: First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations
2024
·
Timothy A. Yap
, Crystal Miller
, et al.
·
Cancer Research
·
2
Abstract 7121: The novel WEE1i, APR-1051, is a potentially well tolerated and effective treatment for cyclin E-overexpressing cancers
2024
·
Molly M. Hansbarger
, Stephen J. Rocca
, et al.
·
Cancer Research
·
2
Abstract C147: The DNA replication checkpoint inhibitors, ATRN-1051 (WEE1i) and ATRN-119 (ATRi), are potentially well tolerated and effective cancer treatments
2023
·
Joseph Vacca
, Stephen Rocca
, et al.
·
Molecular Cancer Therapeutics
·
2
Phase 1 and Dose Expansion Study of APR-246 in Combination with Ibrutinib or Venetoclax-Based Therapy in Subjects with TP53-Mutant Relapsed and/or Refractory Non-Hodgkin Lymphomas (NHL) Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
2020
·
Meghan C. Thompson
, Matthew S. Davids
, et al.
·
Blood
·
2
Abstract B011: Early safety and efficacy of APR-1051, a novel WEE1 inhibitor, in patients with cancer-associated gene alterations: Updated data from ACESOT-1051 phase 1 trial
2025
·
Anthony Tolcher
, David Sommerhalder
, et al.
·
Molecular Cancer Therapeutics
·
1
516MO Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
2021
·
H. Park
, G. Shapiro
, et al.
·
Annals of Oncology
·
1
ATR inhibition induces NF-κB-dependent immunogenicity in Merkel cell carcinoma independent of cGAS-STING
2026
·
Rashmi Bhakuni
, Jung Hyun Lee
, et al.
·
npj Precision Oncology
PDF
Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051).
2026
·
Shiraj Sen
, David Sommerhalder
, et al.
·
Journal of Clinical Oncology
Abstract 2907: A first-in-class series of potent and selective macrocyclic ATR inhibitors
2025
·
Molly M. Hansbarger
, Stephen J. Rocca
, et al.
·
Cancer Research
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults
2025
·
Philip C. Amrein
, Frederic I. Preffer
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
Abstract 7117: Convection enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma
2024
·
Alexander Josowitz
, Teresa Lee
, et al.
·
Cancer Research
Abstract C034: First in Human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors
2023
·
Fiona Simpkins
, Reva Schneider
, et al.
·
Molecular Cancer Therapeutics
Show more works
View as search
Works count:
24
Citation count:
2,518
Year
Topic
Type
